658PPatient reported outcomes (PRO) results from phase II MONO and FAST zolbetuximab (IMAB362) trials in patients with advanced CLDN18.2+ gastric and gastroesophageal junction adenocarcinoma (GA/GEJA). (23rd October 2018) - Morlock, R; Krukas-Hampel, M R; Türeci, Ö